Mahathir Bayena

Dimerix (ASX:DXB) confirmed that BioMarin Pharmaceutical (NASDAQ:BMRN) entered into a definitive agreement to acquire its US commercial licensing partner, Amicus Therapeutics (NASDAQ:FOLD)

The Australian Energy Regulator has launched court proceedings against Origin Energy (ASX:ORG) over alleged breaches of rules governing payments from customers using the government bill-paying service Centrepay.

Ariana Resources (ASX:AA2) has secured up to $11 million in strategic investment and technical support to advance the Dokwe Gold Project in Zimbabwe.

Bitcoin (CRYPTO:BTC) has returned to the spotlight after Citigroup released a wide-ranging price outlook that outlines bullish, base-case, and bearish scenarios for the cryptocurrency over the next 12 months.

Global index provider MSCI has proposed a rule change that could reclassify companies holding more than 50% of assets in cryptocurrencies as funds rather than operating businesses.

XRP (CRYPTO:XRP) is approaching a major structural shift as Ripple advances the XRPL Lending Protocol, positioning the asset at the centre of a new protocol-level credit framework designed for institutional liquidity and large-scale onchain finance.

New York authorities have unveiled a major cryptocurrency fraud case after prosecutors alleged that a sophisticated impersonation scheme siphoned nearly $16 million from Coinbase users across the United States.

The digital euro project has reached technical completion, but political disagreements across Europe continue to delay its official launch.

Outlook Therapeutics (NASDAQ:OTLK) reported its fiscal 2025 results for the year ended September 30, 2025, revealing a net loss of $62.4 million ($1.79 per share) and $1.4 million in revenue from the initial European sales of LYTENAVA in June 2025.

BioMarin Pharmaceutical (NASDAQ:BMRN) and Amicus Therapeutics (NASDAQ:FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction.